Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL

Abstract

Sinusoidal obstruction syndrome is a life-threatening complication that can occur after haematopoietic stem cell transplantation. Defibrotide (DF) has been approved for the treatment of individuals with severe sinusoidal obstruction syndrome following haematopoietic stem cell transplantation in the European Union and the United States. However, the precise mechanisms by which DF protects endothelial cells remain to be elucidated. In this study, we found that DF stimulated angiogenesis in vitro and in vivo as assessed by vascular tube formation, scratch-wound repair and Matrigel plug assays. These effects were associated with an activation of pro-survival signalling pathways, including AKT (protein kinase B), ERK (extracellular signal–regulated kinases) and p38. More importantly, DF alleviated calcineurin inhibitor–induced growth inhibition and apoptosis of human umbilical vein endothelial cells and human hepatic sinusoidal endothelial cells in parallel with upregulation of anti-apoptotic protein B-cell lymphoma–extra-large (Bcl-xL), which was mediated by AKT (protein kinase B). Notably, these effects were abrogated when Bcl-xL was depleted by small interfering RNA (ribonucleic acid). In addition, DF counteracted calcineurin inhibitor–induced activation of nuclear factor-κB and Janus kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) signalling and production of cytokines in vascular endothelial cell–derived EA.hy926 cells. Taken together, DF has pro-angiogenic, anti-apoptotic and anti-inflammatory effects on endothelial cells. DF is a potentially useful agent to prevent the development of, and treat individuals with, endothelial cell injury–related complications after haematopoietic stem cell transplantation.

Keywords

defibrotide - endothelial cells - Bcl-xL - sinusoidal obstruction syndrome - recombinant human soluble thrombomodulin

• References

• 1 McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4 (01) 116-122
• 2 Corbacioglu S, Cesaro S, Faraci M. , et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; 379 (9823): 1301-1309
• 3 Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011; 46 (12) 1495-1502
• 4 Richardson PG, Murakami C, Jin Z. , et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100 (13) 4337-4343
• 5 el Mouelhi M, Kauffman FC. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology 1986; 6 (03) 450-456
• 6 Wang L, Wang CM, Hou LH. , et al. Disruption of the transcription factor recombination signal-binding protein-Jkappa (RBP-J) leads to veno-occlusive disease and interfered liver regeneration in mice. Hepatology 2009; 49 (01) 268-277
• 7 Richardson PG, Corbacioglu S, Ho VT. , et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf 2013; 12 (01) 123-136
• 8 Francischetti IM, Oliveira CJ, Ostera GR. , et al. Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler Thromb Vasc Biol 2012; 32 (03) 786-798
• 9 Strouse C, Richardson P, Prentice G. , et al. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2016; 22 (07) 1306-1312
• 10 Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol 2001; 106 (1–2): 57-68
• 11 Corbacioglu S, Carreras E, Mohty M. , et al. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the International Compassionate-Use Program. Biol Blood Marrow Transplant 2016; 22 (10) 1874-1882
• 12 Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17 (08) 1636-1642
• 13 Eissner G, Multhoff G, Gerbitz A. , et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002; 100 (01) 334-340
• 14 Palomo M, Mir E, Rovira M, Escolar G, Carreras E, Diaz-Ricart M. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood 2016; 127 (13) 1719-1727
• 15 Nakamura D, Yoshimitsu M, Kawada H. , et al. Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47 (03) 463-464
• 16 Yamamoto S, Yagawa A, Toyama D. , et al. Successful treatment of hepatic sinusoidal obstructive syndrome after hematopoietic stem cell transplantation in a child using recombinant thrombomodulin. Acta Haematol 2013; 129 (01) 62-64
• 17 Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45 (04) 783-785
• 18 Ikezoe T, Yang J, Nishioka C, Honda G, Furihata M, Yokoyama A. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol 2012; 32 (09) 2259-2270
• 19 Pan B, Wang X, Kojima S. , et al. The fifth epidermal growth factor like region of thrombomodulin alleviates LPS-induced sepsis through interacting with GPR15. Thromb Haemost 2017; 117 (03) 570-579
• 20 Pan B, Wang X, Kojima S. , et al. The fifth epidermal growth factor-like region of thrombomodulin alleviates murine graft-versus-host disease in a G-protein coupled receptor 15 dependent manner. Biol Blood Marrow Transplant 2017; 23 (05) 746-756
• 21 Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001; 167 (03) 1644-1653
• 22 Ikezoe T, Tanosaki S, Krug U. , et al. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004; 104 (01) 237-242
• 23 Ikezoe T, Yang J, Nishioka C. , et al. The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model. Bone Marrow Transplant 2017; 52 (01) 73-79
• 24 Shi CS, Shi GY, Chang YS. , et al. Evidence of human thrombomodulin domain as a novel angiogenic factor. Circulation 2005; 111 (13) 1627-1636
• 25 Pan B, Wang X, Nishioka C. , et al. G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin. Sci Rep 2017; 7 (01) 692
• 26 Sessa WC. Molecular control of blood flow and angiogenesis: role of nitric oxide. J Thromb Haemost 2009; 7 (Suppl. 01) 35-37
• 27 Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399 (6736): 601-605
• 28 Richardson PG, Ho VT, Giralt S. , et al. Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol 2012; 3 (04) 253-265
• 29 Deleve LD. Sinusoidal obstruction syndrome. Gastroenterol Hepatol (N Y) 2008; 4 (02) 101-103
• 30 Sena CM, Pereira AM, Seiça R. Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim Biophys Acta 2013; 1832 (12) 2216-2231
• 31 Sawa Y, Ueki T, Hata M. , et al. LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 expression in human lymphatic endothelium. J Histochem Cytochem 2008; 56 (02) 97-109
• 32 Benimetskaya L, Wu S, Voskresenskiy AM. , et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008; 112 (10) 4343-4352
• 33 Koehl GE, Geissler EK, Iacobelli M. , et al. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther 2007; 6 (05) 686-690
• 34 Mitsiades CS, Rouleau C, Echart C. , et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res 2009; 15 (04) 1210-1221
• 35 Tocchetti P, Tudone E, Marier JF, Marbury TC, Zomorodi K, Eller M. Pharmacokinetic profile of defibrotide in patients with renal impairment. Drug Des Devel Ther 2016; 10: 2631-2641
• 36 Watanabe E, Yamazaki S, Setoguchi D. , et al. Pharmacokinetics of standard- and reduced-dose recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation during continuous hemodiafiltration. Front Med (Lausanne) 2017; 4: 15
• 37 Tsuruta K, Yamada Y, Serada M, Tanigawara Y. Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects. J Clin Pharmacol 2011; 51 (09) 1276-1285